Understanding genetic and environmental factors in pulmonary fibrosis
Official title: Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland [PRECISE-PF]
Run by Royal College of Surgeons, Ireland · NCT06702228 · Data updated 2026-11-12
This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Royal College of Surgeons, Ireland Academic / other |
| Locations | 1 site (Dublin) |
| Status | Recruiting |
| Started | September 28, 2021 |
| Main results expected | July 1, 2026 |
| Study ends | April 1, 2028 |
| Registry record updated | November 22, 2024 |
| Trial ID | NCT06702228 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a multidisciplinary team diagnosis of fibrotic interstitial lung disease or idiopathic pulmonary fibrosis, as well as those with specific connective tissue diseases.
✕Probably not a fit
Patients currently participating in interventional clinical trials or those with acute or chronic hypersensitivity pneumonitis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on improving the understanding of how genetic and environmental factors contribute to pulmonary fibrosis. It aims to identify specific genes and other risk factors that may influence the development and progression of this disease. Participants will undergo various assessments, including genetic testing, CT scans, and quality of life questionnaires, to gather comprehensive data on their condition. The study will involve patients diagnosed with fibrotic interstitial lung diseases, including idiopathic pulmonary fibrosis.
Why it matters
Potential benefit: If successful, this study could lead to better diagnostic tools and personalized care strategies for patients with pulmonary fibrosis.
How similar studies have gone: Other studies have shown promise in understanding genetic influences on pulmonary fibrosis, but this approach may offer novel insights specific to familial cases.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able and willing to give written informed consent. * An MDT diagnosis of fibrotic ILD which fall into one of the following three catagories; 1. Have a multidisciplinary team (MDT) diagnosis of a fibrotic interstitial lung disease, reporting one or more relatives with a fibrotic form of ILD 2. Have a MDT diagnosis of IPF in accordance with consensus criteria, ATS, ERS, JRS, ALAT guidelines without a family history of pulmonary fibrosis. 3. Meet the American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis, scleroderma, Sjogren's syndrome, idiopathic inflammatory myopathy and systemic lupus erythematosus. Exclusion Criteria: * Currently participating in an interventional clinic trial. * Change in clinical phenotype from initial radiological diagnosis to screening. * Acute or chronic hypersensitivity pneumonitis with consensus criteria (appropriate exposure history, radiological features ± avian and fungal precipitins). * Asbestosis (appropriate occupational history and radiological evidence of asbestos exposure) * Life expectancy for any disease, including ILD \<12 months (investigator assessment) * Major extrapulmonary physiological restriction (e.g. chest wall abnormality, large pleural effusion)
Where it's running
-
Beaumont Hospital
Dublin, Ireland Recruiting
Study contacts
- Principal investigator: Killian Hurley — Rcsi
- Study coordinator: Killian Hurley
- Email: killianhurley@rcsi.ie
- Phone: +35318093000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biobank for interstitial lung diseases
This study is setting up a collection of health information and samples from patients with interstitial lung diseases to help researchers learn more about the condition and find better treatments.
-
Registry for individuals affected by pulmonary fibrosis
This study invites people with pulmonary fibrosis, along with their caregivers and family members, to share their experiences through online surveys to help researchers understand the condition better and possibly reach out for future studies.
-
AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.
-
Advanced imaging to see how immunosuppression affects lung fibrosis activity
This trial will test whether immunosuppression changes PET and MRI measurements of active collagen deposition and tissue injury in people with non‑IPF interstitial lung disease who are starting treatment.
-
Early detection of progressive lung fibrosis in connective tissue diseases
This project will test whether blood extracellular vesicle biomarkers combined with AI-analyzed HRCT scans can detect and predict progressive interstitial lung disease in adults with connective tissue diseases.
-
Using capillaroscopy to help diagnose diffuse interstitial pneumonias
We will test whether adding nailfold capillaroscopy to standard care helps doctors diagnose connective-tissue–related interstitial lung disease faster in adults newly diagnosed with pulmonary interstitial disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.